The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 11, 2025

Filed:

Mar. 04, 2024
Applicant:

Othair Prothena Limited, Dublin, IE;

Inventors:

Robin Barbour, Walnut Creek, CA (US);

Gene Kinney, Boca Raton, FL (US);

Wagner Zago, San Carlos, CA (US);

Tarlochan S. Nijjar, Orinda, CA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 38/00 (2006.01); A61K 39/39 (2006.01); A61P 25/28 (2006.01); A61P 37/04 (2006.01); C07K 14/47 (2006.01);
U.S. Cl.
CPC ...
C07K 14/4711 (2013.01); A61K 39/0007 (2013.01); A61K 39/39 (2013.01); A61P 25/28 (2018.01); A61P 37/04 (2018.01); A61K 2039/53 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/55544 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/55577 (2013.01); A61K 2039/575 (2013.01); A61K 2039/6037 (2013.01); C07K 2319/00 (2013.01);
Abstract

The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of Aβ and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide.


Find Patent Forward Citations

Loading…